Navamedic Future Growth
Future criteria checks 4/6
Navamedic is forecast to grow earnings and revenue by 29.6% and 12.3% per annum respectively. EPS is expected to grow by 1.6% per annum. Return on equity is forecast to be 17.2% in 3 years.
Key information
29.6%
Earnings growth rate
1.6%
EPS growth rate
| Pharmaceuticals earnings growth | 19.6% |
| Revenue growth rate | 12.3% |
| Future return on equity | 17.2% |
| Analyst coverage | Low |
| Last updated | 15 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 655 | 52 | 14 | 29 | 2 |
| 12/31/2025 | 569 | 32 | -7 | 8 | 2 |
| 12/31/2024 | 519 | 25 | 38 | 43 | 2 |
| 9/30/2024 | 526 | 20 | 7 | 9 | N/A |
| 6/30/2024 | 543 | 27 | 3 | 6 | N/A |
| 3/31/2024 | 511 | -11 | -9 | -6 | N/A |
| 12/31/2023 | 512 | 3 | 0 | 2 | N/A |
| 9/30/2023 | 503 | 31 | 47 | 47 | N/A |
| 6/30/2023 | 454 | 23 | 31 | 33 | N/A |
| 3/31/2023 | 441 | 43 | 37 | 40 | N/A |
| 12/31/2022 | 382 | 29 | 16 | 18 | N/A |
| 9/30/2022 | 356 | 12 | 7 | 9 | N/A |
| 6/30/2022 | 327 | 8 | 2 | 2 | N/A |
| 3/31/2022 | 283 | 4 | -8 | -7 | N/A |
| 12/31/2021 | 278 | 1 | -2 | -1 | N/A |
| 9/30/2021 | 244 | -7 | 1 | 2 | N/A |
| 6/30/2021 | 237 | -6 | -1 | 2 | N/A |
| 3/31/2021 | 213 | -8 | -4 | 0 | N/A |
| 12/31/2020 | 210 | -16 | -8 | -3 | N/A |
| 9/30/2020 | 202 | -22 | -20 | -16 | N/A |
| 6/30/2020 | 194 | -24 | -18 | -15 | N/A |
| 3/31/2020 | 199 | -26 | -13 | -12 | N/A |
| 12/31/2019 | 189 | -16 | 12 | 13 | N/A |
| 9/30/2019 | 193 | -1 | 1 | 4 | N/A |
| 6/30/2019 | 189 | 0 | 5 | 5 | N/A |
| 3/31/2019 | 187 | 10 | -1 | -1 | N/A |
| 12/31/2018 | 184 | 4 | -38 | -38 | N/A |
| 9/30/2018 | 177 | -20 | -26 | -20 | N/A |
| 6/30/2018 | 178 | -13 | N/A | -11 | N/A |
| 3/31/2018 | 222 | -20 | N/A | 41 | N/A |
| 12/31/2017 | 258 | -16 | N/A | 59 | N/A |
| 9/30/2017 | 294 | 3 | N/A | 43 | N/A |
| 6/30/2017 | 315 | 4 | N/A | 29 | N/A |
| 3/31/2017 | 292 | -9 | N/A | -13 | N/A |
| 12/31/2016 | 274 | -11 | N/A | -15 | N/A |
| 9/30/2016 | 258 | -28 | N/A | -8 | N/A |
| 6/30/2016 | 254 | -30 | N/A | -7 | N/A |
| 3/31/2016 | 247 | -17 | N/A | 10 | N/A |
| 12/31/2015 | 248 | -11 | N/A | 23 | N/A |
| 9/30/2015 | 245 | -4 | N/A | 24 | N/A |
| 6/30/2015 | 242 | 1 | N/A | 8 | N/A |
| 3/31/2015 | 242 | 1 | N/A | -9 | N/A |
| 12/31/2014 | 223 | -1 | N/A | -11 | N/A |
| 9/30/2014 | 204 | 1 | N/A | -12 | N/A |
| 6/30/2014 | 182 | -2 | N/A | -8 | N/A |
| 3/31/2014 | 161 | -3 | N/A | -16 | N/A |
| 12/31/2013 | 152 | -1 | N/A | -16 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0FDB's forecast earnings growth (29.6% per year) is above the savings rate (2.1%).
Earnings vs Market: 0FDB's earnings (29.6% per year) are forecast to grow faster than the UK market (14.6% per year).
High Growth Earnings: 0FDB's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 0FDB's revenue (12.3% per year) is forecast to grow faster than the UK market (3.5% per year).
High Growth Revenue: 0FDB's revenue (12.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 0FDB's Return on Equity is forecast to be low in 3 years time (17.2%).